Interaction of monocytes from patients with psoriatic arthritis with cultured microvascular endothelial cells.

The aim of this study was to investigate the interaction of monocytes of the peripheral blood of patients with psoriatic arthritis with cultured human dermal microvascular endothelial cells (HDMEC) compared to monocytes from control persons. The surface expression of adhesion molecules (ADM) and other cell surface molecules in psoriatic arthritis and control monocytes was investigated by quantitative flow cytometry. The receptor densities of these molecules were determined in terms of monoclonal antibody (mAb) binding sites. Cocultivation experiments including peripheral blood mononuclear cells and HDMEC were performed to determine the adhesion to and transmigration through activated or resting endothelial cell monolayers. In order to achieve optimal responses of cellular functions, activation for adhesion experiments was induced by lipopolysaccharide (LPS), while in transmigration experiments the endothelial cells were activated by TNF-alpha. For transendothelial migration studies HDMEC cultivated on collagen gels were used. In the supernatants of cocultivated cells the cytokines IL-6 and IL-8 were determined by ELISA. A significantly reduced expression of CD11b in nonactivated psoriatic arthritis peripheral blood monocytes compared to control monocytes was verified (mean number of adhesion molecules/cell: 33,756 +/- 10,138 vs 61,023 +/- 6925). In agreement with these findings, adhesion to, as well as transendothelial migration through, activated HDMEC was found to be significantly reduced in psoriatic arthritis monocytes. Transendothelial migration engendered an enrichment of monocytes in the migrated cell fraction for both control and psoriatic arthritis peripheral blood mononuclear cells. The activation of HDMEC by LPS induced a highly significantly enhanced cytokine release for IL-6 and IL-8, irrespective of the origin of monocytes (psoriatic arthritis vs. controls). However, IL-8 production in the supernatants of nonactivated monocytes/HDMEC cocultures was significantly reduced in the case of monocytes from psoriatic arthritis patients (6650 +/- 2489.32 pg/ml) vs 9280.00 +/- 3209.51 pg/ml in control patients. Impaired adhesion as well as transendothelial migration of monocytes derived from peripheral blood of psoriatic arthritis patients can be explained by the reduced expression of adhesion molecules MAC-1 (CD11b/CD18) at the surface of monocytes. The reduced IL-8 production also corresponds to a diminished cellular interaction under nonflow conditions. These results support the view that there are systemic immunological alterations in psoriatic arthritis patients.

Influence of acetylsalicylic acid on oxidation of native and glycated low-density lipoprotein.

It is generally accepted that oxidation of low-density lipoproteins (LDL) is a causal factor in the development of atherosclerosis. Non-enzymatic glycosylation of LDL, i.e."glycation", plays a central role in late complications of diabetes mellitus and may initiate and/or accelerate the oxidation process. Therefore, the inhibition of this processes is of major therapeutic relevance. The influence of acetylsalicylic acid (ASA) on the oxidation of native and glycated LDL was studied in vitro. LDL (0.25 mg protein/ml ) was oxidatively modified with 5.0 microM CuSO4. Only at "supratherapeutical" ASA concentrations in the range 0.06-2.0 mg /ml we found a significant concentration-dependent inhibition of LDL oxidation both for native and glycated LDL, which was from 0.2 mg/ml upwards significantly more marked for native LDL than for glycated LDL. The maximal inhibitory effect occurred at 2.0 mg/ml with 89.6% inhibition of LDL-oxidation for native LDL and 64.4% for glycated LDL. At 0.2 mg/ml ASA the respective inhibitory values were 38.5% and 31.0%. For glycated LDL the ASA doses of maximal- and approximately 50%-inhibition, as found for native LDL, were chosen to investigate the inhibitory effect on 2,4,8 and 24 hours oxidation of glycated LDL to monitor the time-dependency of inhibition by ASA. This revealed that ASA only delayed, not permanently inhibited LDL oxidation.

Do E-series prostaglandins and their metabolites influence oxidation of native and glycated low-density lipoproteins?

Oxidation of lipoproteins, and, in particular, low-density lipoproteins (LDL), has been shown to play a significant role in the pathogenesis of atherosclerosis. Oxidized LDL are endocytosed via scavenger receptors to form lipid-laden foam cells. The non-enzymatic reaction of glucose with proteins and lipoproteins results in a modified LDL involved in the pathogenesis of late complications in diabetes mellitus. In the present paper, the influence of various E-series prostaglandins (PGE1; 13,14-dihydro PGE1; 13,14-dihydro 15-keto PGE1; and PGE2) on oxidation of native and glycated LDL was investigated. The effect of these agents in the concentration range from 1 pg/mL to 1.6 micrograms/mL on copper-induced oxidation of native and glycated LDL was tested. The concentration of each agent causing the maximal effect on oxidation of native LDL, as measured by the formation of thiobarbituric acid-reacting substances, was chosen to estimate the effect on 2, 4, 8, and 24 h oxidation of glycated LDL. The study was performed with LDL isolated by sequential ultracentrifugation from normolipidemic individuals. LDL (0.25 mg protein/mL) was oxidatively modified with 5 microM CuSO4. The glycosylation of LDL was performed by incubation of LDL with 500 mM glucose for varying periods of time ranging from 10 to 31 days. Our results show that only 13,14-dihydro PGE1 significantly inhibits copper-induced oxidation of native LDL, while the other examined E-series prostaglandins in vitro are ineffective as reducing agents in LDL-oxidation.

Modulation of nitric oxide synthase activity by ibuprofen.

Inhibition of NO synthesis represents a new therapeutical approach in the treatment of inflammation. Clinical use of NOS inhibitors will necessitate the design of drugs selective for iNOS, because inhibition of constitutive endothelial NOS may cause adverse cardiovascular side effects. This study examines the effect of ibuprofen and its stereoeisomeric components on the activation of iNOS and cNOS as well as on the NO production by human umbilical vein endothelial cells. At therapeutic concentrations Ibuprofen activated iNOS and inhibited NOS. In endothelial cell culture experiments activation of NO production was seen especially at supratherapeutic ibuprofen concentrations. Both stereoisomeric components of ibuprofen showed comparable effects. This drug can therefore not be used for the selective inhibition of iNOS.

Leukosialin (CD43)-major histocompatibility class I molecule interactions involved in spontaneous T cell conjugate formation.

Resting T cells spontaneously adhere in a selective manner to potent accessory cells, such as dendritic cells (DC) and lymphoblastoid B blasts (LCL). Here we demonstrate that leukosialin (CD43) and major histocompatibility complex class I molecules (MHC-I) might play a critical role in this process. T cell conjugate formation with monocyte-derived DC (md-DC) and LCL could be strongly inhibited by either preincubating T cells with Fab fragments of CD43 monoclonal antibody (mAb) 6F5 or by preincubating md-DC or LCL with MHC-I mAb W6/32. Intact CD43 mAb 6F5, in contrast to monovalent Fab fragments, enhanced T cell adhesiveness by transactivating CD2 binding to CD58 molecules. Interestingly, induction of this proadhesive signal via CD43 with intact 6F5 mAb was found to revert mAb W6/32-mediated inhibition of T cell conjugate formation. These observations indicated that CD43 cross-linkage mimics and monovalent mAb 6F5 inhibits interaction of T cell CD43 with a stimulatory ligand on opposing cells, presumably MHC-I. For the demonstration of direct physical interaction between CD43 on T cells and MHC-I-coated beads it was necessary, however, to ligate CD2 on T cells with a stimulatory pair of CD2 mAbs (VIT13 plus TS2/18). This suggests that CD2 ligation crosswise upregulates CD43 binding avidity for MHC-I and that both adhesion molecule pairs (CD43/MHC-I and CD2/CD58) act in concert to induce and mediate T cell conjugate formation with certain cell types.

Mode of action of coumarin in immune cells.

In order to characterize further the mode of action of coumarin, binding studies were undertaken using human monocytes and radioactively labelled drug. Since coumarin is only a small compound and we wanted to exclude possible artefacts due to variations in size or conformation, the drug was produced by synthesis in the presence of radioactive 14C. Adding increasing amounts of a mixture of labelled and unlabelled drug to monocytes resulted in saturating conditions only at rather high concentrations. Performing Scatchard analysis demonstrated that binding sites for coumarin appeared to be present in relatively high numbers (7.5 x 10(8)/cell) but their affinity was rather low (K alpha approximately 2 x 10(2) M-1). Inhibition studies with 7-hydroxycoumarin revealed that an approximately four times higher molar concentration of the derivative was necessary to cause 50% displacement of coumarin from its binding site. These results indicate that binding of the drug to cells is characterized by high-capacity but low-affinity conditions. This would be compatible with the hypothesis that coumarin interacts with ubiquitous intracellular receptor proteins able to interact with aromatic hydrocarbons, which might form the basis for enzyme induction, and leads to the effects observed in vitro and in vivo.

Differences in anti-Fab antibodies in adult and late onset rheumatoid arthritis.

In the present study the ratio of antigen-bound anti-IgG-Fab antibodies (hidden aFab) to free aFab was found to be significantly increased in patients with adult onset rheumatoid arthritis (AORA) as compared to late onset rheumatoid arthritis (LORA). The overall amount of aFab was similar in both groups. The difference was only seen in seropositive patients. Within the seropositive AORA group, the aFab ratio was correlated with the duration and the stage of disease but not with the patients' age at investigation. This might reflect a higher affinity of anti-Fab antibodies and/or a greater diversity of the idiotypic repertoire in adult onset disease resulting in the formation of immune complexes, the stability of which might be enhanced further by the presence of rheumatoid factors. Although a pathophysiological involvement of aFab cannot be concluded from our observations, it is conceivable that different immunoregulatory mechanisms could be operative in RA with onset at different ages.

A method to differentiate between anti-C1q antibodies and C1q-binding immune complexes using collagenase-digested solid phase C1q.

A method for the detection of circulating immune complexes in the presence of autoantibodies to C1q is described. Solid phase C1q-digestion with bacterial collagenase results in the elimination of the collagen-like region of C1q. Binding of model immune complexes to this modified solid phase C1q is practically unaltered, while reactivity of anti-C1q antibodies is abolished by this procedure. In conjunction with an ELISA using the collagen-like region of C1q as antigen this modified C1q solid phase assay may be used to determine immune complexes and anti-C1q antibodies in the sera of patients with autoimmune rheumatic diseases.

Inhibition of complement activation in aged individuals due to increased plasma fibronectin concentration.

The influence of fibronectin levels on complement activation by immune complexes and non-immune activators in elderly humans was investigated. The present study demonstrates for the first time a shift in complement activation from the classical to the alternative pathway, if the fibronectin concentration rises above a certain level (near 1 mg/ml). Plasma of elderly individuals often contains large amounts of fibronectin, the reason for which is unknown. While C1 consumption is inhibited under these conditions, C3 depletion remains largely unaffected. This could be due to a compensatory triggering of the alternative reaction sequence caused by fibronectin deposition at and blockade of C1-activating sites. Probable physiologic implications of this changed complement activation pattern are discussed.

Demonstration of collagen type conversion in culture supernatants from human chondrocytes by an inhibition ELISA.

Culture supernatants from monolayer cultures of human chondrocytes were tested for the presence of collagen type I and type II during subpassaging using an inhibition Elisa. The sensitivity of the Elisa was 404 +/- 50 ng/ml (mean +/- SEM) for the determination of type I collagen and 112 +/- 16 ng/ml for type II collagen. Whereas using immunofluorescence techniques, type II collagen was observed in human chondrocytes cultured under monolayer conditions only up to the first subpassage (1), in culture supernatants from human chondrocytes type II collagen could be found up to the fourth subpassage. Type I collagen was detectable in supernatants from the beginning of primary cultures and was present up to the tenth subpassage in increasing concentrations. Variations in the amount of collagen present in the culture supernatants seemed in part to be due to different growth characteristics of the chondrocytes. Cell shape was not associated with the release of a particular collagen type. In summary, the collagen inhibition Elisa appears to be equivalent to biochemical methods with regard to sensitivity and specificity. Investigations on influencing the switch in collagen production in human chondrocytes may benefit from the use of both techniques described.

Change in collagen synthesis of human chondrocyte culture. I. Development of a human model, demonstration of collagen type conversion by immunofluorescence.

A research system constituted entirely of components of human origin was developed to study conversion of collagen synthesis by human chondrocytes. Type specificity of affinity chromatography-purified antibodies to human type II or type I collagen was proven by ELISA inhibition and immunofluorescence analysis. Human chondrocytes were isolated from articular cartilage and kept in monolayer cultures for eight subpassages. Conversion of type II to type I synthesis by chondrocytes was investigated by immunofluorescence. Staining with anti-type II collagen antibodies could be detected during primary cultures and in the first subpassage, whereas staining with anti-type I collagen antibodies occurred beginning from the end of primary cultures and was present up to the eighth subpassage. Results are compared to observations obtained in animal systems and their relevance to conditions in osteoarthritis is discussed.

Association of C1q- and conglutinin-binding immune complexes with high consumption of alpha-2-macroglobulin in synovial fluids of patients with rheumatoid arthritis.

The consumption of alpha-2-macroglobulin (a2M) by proteinases in synovial fluids (SF) was indirectly measured by determining trypsin binding to solid-phase immunoadsorbed SF-a2M. In addition immune complexes (IC) were assessed by the solid-phase C1q-binding assay as well as the solid-phase conglutinin binding assay in rheumatoid (RA; n = 25) and osteoarthritic (OA; n = 9) SF. Elevated levels were found as follows: a2M X proteinase complexes (a2M X P) in 73.5% (RA, n = 20; OA, n = 5), solid-phase C1q-binding IC (C1q-IC) in 52% (13 out of 25 RA-SF) and bovine conglutinin binding IC (KgB-IC) in 54% (13 out of 24 RA-SF). All OA-SF were in either IC assay negative. Consumption of a2M in OA-SF and seronegative RA-SF was not more than 15% of total SF-a2M, showing a mean value of 19.5 and 13.5 micrograms a2M X P/ml SF. Seropositive RA-SF had an a2M X P mean value of 96.4 micrograms/ml SF, which differed significantly (p less than or equal to 0.05) from the former two groups. Similarly, RA-SF which were negative in either IC assay had a low a2M X P mean value (20.0 micrograms/ml SF). This contrasted sharply with the a2M X P means obtained in IC-positive RA-SF, which amounted to 131.5 micrograms a2M X P/ml SF in C1q-IC positive RA-SF and to 110.4 micrograms a2M X P/ml SF in KgB-IC positive RA-SF, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)